COVID 19 Vaccine: Novavax Received up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
Funds clinical development of NVX-CoV2373 through Phase 2 Supports rapid scale-up of vaccine manufacturing Allows for increased production of Matrix-M adjuvant Reserves global large-scale manufacturing capacity Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company...
